Adeia Inc. (ADEA)
NASDAQ: ADEA · Real-Time Price · USD
12.49
-0.46 (-3.55%)
Aug 1, 2025, 12:09 PM - Market open
Aerovate Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Aerovate Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $19.5, which forecasts a 56.12% increase in the stock price over the next year. The lowest target is $17 and the highest is $26.
Price Target: $19.50 (+56.12%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aerovate Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BWS Financial | BWS Financial | Strong Buy Maintains $18 | Strong Buy | Maintains | $18 | +44.12% | Jul 9, 2025 |
| Roth Capital | Roth Capital | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +108.17% | Jun 20, 2025 |
| BWS Financial | BWS Financial | Strong Buy Maintains $18 | Strong Buy | Maintains | $18 | +44.12% | May 6, 2025 |
| Rosenblatt | Rosenblatt | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +36.11% | May 6, 2025 |
| BWS Financial | BWS Financial | Strong Buy Maintains $18 | Strong Buy | Maintains | $18 | +44.12% | Apr 15, 2025 |
Financial Forecast
Revenue This Year
413.66M
from 376.02M
Increased by 10.01%
Revenue Next Year
431.94M
from 413.66M
Increased by 4.42%
EPS This Year
1.40
from 0.57
Increased by 144.89%
EPS Next Year
1.48
from 1.40
Increased by 6.20%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 431.3M | 446.3M | 473.5M |
| Avg | 413.7M | 431.9M | 459.9M |
| Low | 389.8M | 412.0M | 441.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 14.7% | 7.9% | 9.6% |
| Avg | 10.0% | 4.4% | 6.5% |
| Low | 3.7% | -0.4% | 2.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.45 | 1.55 | 1.79 |
| Avg | 1.40 | 1.48 | 1.73 |
| Low | 1.33 | 1.40 | 1.67 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 154.2% | 11.3% | 20.4% |
| Avg | 144.9% | 6.2% | 17.0% |
| Low | 132.8% | 0.4% | 12.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.